Review clinical evidence and evolving roles of middle meningeal artery embolization in chronic subdural hematoma, highlighting current uncertainties.
Key Takeaways
- While some randomized trials suggest a reduction in recurrence or treatment failure
- Implementation is influenced by procedural risks, resource requirements, and cost considerations
- MMAE represents a promising but emerging strategy that could complement current therapies